Organon & Co. (OGN) Announces American Academy of Dermatology’s Strong Recommendation for VTAMA Cream
Organon & Co. (NYSE:OGN) is one of the 13 Best Healthcare Stocks to Buy Under $10. On July 7, Organon & Co. (NYSE:OGN) announced that its VTAMA (tapinarof) cream, 1%, attained a strong recommendation in the American Academy of Dermatology’s (AAD) 2025 focused guideline update for the management of adults with moderate to severe atopic dermatitis (AD).
A pharmacist wearing a white lab coat and a face mask dispenses biosimilars at a pharmacy.
Organon & Co. (NYSE:OGN) stated that the recommendation highlights the cream’s status as a steroid-free and effective option for daily disease management. It does not have precautions or label warnings, no restrictions on use duration or percentage of body surface area affected, and no contraindications.
Organon & Co. (NYSE:OGN) is a global pharmaceutical company that develops and delivers innovative health solutions via a portfolio of prescription therapies within women’s health, established brands, and biosimilars.
While we acknowledge the potential of OGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
Content Original Link:
" target="_blank">
